Logo image of TENX

TENAX THERAPEUTICS INC (TENX) Stock Fundamental Analysis

NASDAQ:TENX - Nasdaq - US88032L6056 - Common Stock - Currency: USD

6.22  +0.17 (+2.81%)

Fundamental Rating

3

TENX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. While TENX has a great health rating, there are worries on its profitability. TENX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TENX has reported negative net income.
In the past year TENX has reported a negative cash flow from operations.
In the past 5 years TENX always reported negative net income.
In the past 5 years TENX always reported negative operating cash flow.
TENX Yearly Net Income VS EBIT VS OCF VS FCFTENX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of TENX (-21.61%) is better than 77.42% of its industry peers.
TENX has a Return On Equity of -22.15%. This is amongst the best in the industry. TENX outperforms 83.69% of its industry peers.
Industry RankSector Rank
ROA -21.61%
ROE -22.15%
ROIC N/A
ROA(3y)-136.22%
ROA(5y)-220.51%
ROE(3y)-284.78%
ROE(5y)-368.86%
ROIC(3y)N/A
ROIC(5y)N/A
TENX Yearly ROA, ROE, ROICTENX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

TENX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TENX Yearly Profit, Operating, Gross MarginsTENX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, TENX has more shares outstanding
TENX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for TENX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TENX Yearly Shares OutstandingTENX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
TENX Yearly Total Debt VS Total AssetsTENX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of 1.76, we must say that TENX is in the distress zone and has some risk of bankruptcy.
TENX has a Altman-Z score of 1.76. This is in the better half of the industry: TENX outperforms 71.33% of its industry peers.
There is no outstanding debt for TENX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.76
ROIC/WACCN/A
WACCN/A
TENX Yearly LT Debt VS Equity VS FCFTENX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 40.48 indicates that TENX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 40.48, TENX belongs to the best of the industry, outperforming 98.92% of the companies in the same industry.
TENX has a Quick Ratio of 40.48. This indicates that TENX is financially healthy and has no problem in meeting its short term obligations.
TENX's Quick ratio of 40.48 is amongst the best of the industry. TENX outperforms 98.92% of its industry peers.
Industry RankSector Rank
Current Ratio 40.48
Quick Ratio 40.48
TENX Yearly Current Assets VS Current LiabilitesTENX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.64% over the past year.
EPS 1Y (TTM)90.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TENX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.87% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y79.36%
EPS Next 2Y33.61%
EPS Next 3Y21.83%
EPS Next 5Y16.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TENX Yearly Revenue VS EstimatesTENX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2027 2028 2029 2030 2031 2032 200M 400M 600M
TENX Yearly EPS VS EstimatesTENX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5K -10K -15K -20K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TENX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TENX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TENX Price Earnings VS Forward Price EarningsTENX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TENX Per share dataTENX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

A more expensive valuation may be justified as TENX's earnings are expected to grow with 21.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.61%
EPS Next 3Y21.83%

More info and screens

0

5. Dividend

5.1 Amount

TENX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TENAX THERAPEUTICS INC

NASDAQ:TENX (6/2/2025, 12:11:41 PM)

6.22

+0.17 (+2.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners61.26%
Inst Owner Change47.28%
Ins Owners0.28%
Ins Owner Change0%
Market Cap25.81M
Analysts88
Price Target22.44 (260.77%)
Short Float %7.45%
Short Ratio11.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.12%
Min EPS beat(2)-41.99%
Max EPS beat(2)58.23%
EPS beat(4)3
Avg EPS beat(4)28.11%
Min EPS beat(4)-41.99%
Max EPS beat(4)86.6%
EPS beat(8)5
Avg EPS beat(8)11.58%
EPS beat(12)7
Avg EPS beat(12)12.99%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)37.5%
EPS NQ rev (1m)-16.13%
EPS NQ rev (3m)69.1%
EPS NY rev (1m)-25.19%
EPS NY rev (3m)60.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB 0.24
EV/EBITDA N/A
EPS(TTM)-2.48
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-4
FCFYN/A
OCF(TTM)-4
OCFYN/A
SpS0
BVpS26.34
TBVpS26.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.61%
ROE -22.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-136.22%
ROA(5y)-220.51%
ROE(3y)-284.78%
ROE(5y)-368.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 40.48
Quick Ratio 40.48
Altman-Z 1.76
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.03%
EPS Next Y79.36%
EPS Next 2Y33.61%
EPS Next 3Y21.83%
EPS Next 5Y16.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-153.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-53.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-53.82%
OCF growth 3YN/A
OCF growth 5YN/A